Viewing data from:

LUPRON DEPOT

NDA

LEUPROLIDE ACETATE | N020517 | ABBVIE ENDOCRINE INC

3 strengths2 unique patents0 unique exclusivities

Patent Timeline

2 unique patents by expiration date

Active (2)Today

2027

2028

2029

2030

2031

Today

8921326

Feb. 5, 2031

9617303

Mar. 22, 2028

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

205 trials from ClinicalTrials.gov — 3 recruiting, 17 active, 129 completed

Trial	Phase	Status	Sponsor	Enrollment	Dates
Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer NCT03902951	Phase 2	Active	Jonsson Comprehensive Cancer Center	28	2021-03-17 → 2028-01-01
Management of Castration-Resistant Prostate Cancer with Oligometastases NCT02685397	Phase 2/3	Active	Sir Mortimer B. Davis - Jewish General Hospital	102	2016-10 → 2041-08
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer NCT00430183	Phase 3	Active	Alliance for Clinical Trials in Oncology	788	2007-05-08 → 2030-10
A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer NCT04194554	Phase 1/2	Active	University of Michigan Rogel Cancer Center	102	2020-11-06 → 2029-05
FACILE: FeAsibility of First-line RiboCIclib in OLdEr Patients with Advanced Breast Cancer NCT03944434	Phase 2	Active	Fondazione Sandro Pitigliani	116	2018-12-27 → 2025-11-27
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)NCT02319837	Phase 3	Active	Pfizer	1,068	2014-12-17 → 2026-09-19
REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer NCT03951831	Phase 2	Active	Mark Stein	26	2019-05-16 → 2028-04
Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer NCT01786265	Phase 2	Active	M.D. Anderson Cancer Center	310	2013-02-05 → 2027-02-01
Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer NCT00544830	Phase 2	Active	City of Hope Medical Center	29	2006-07-18 → 2027-02-15
Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer NCT02023463	Phase 1	Active	Thomas Jefferson University	25	2014-04-02 → 2040-01-01

Source: ClinicalTrials.gov. Trials matched by ingredient name.

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 1 NDC

Highest NADAC/Unit

$6516.30

per ea

Lowest NADAC/Unit

$6516.30

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
00074334603LUPRON DEPOT 22.5 MG 3MO KIT	$6516.30	EA	Brand	—	2026-01-02

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 6 NDCs (3 FSS, 3 Big4)

Lowest Price

$376.88

Highest Price

$753.77

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
00074-3346-03LUPRON DEPOT 3-MONTH 22.5MG	$376.88	FSS	Abbvie US LLC	07/31/2030
00074-3346-03LUPRON DEPOT 3-MONTH 22.5MG	$376.88	Big4	Abbvie US LLC	07/31/2030
00074-3683-03LUPRON DEPOT 4-MONTH, 30MG KIT (4X7.5MG)	$502.51	FSS	Abbvie US LLC	07/31/2030
00074-3683-03LUPRON DEPOT 4-MONTH, 30MG KIT (4X7.5MG)	$502.51	Big4	Abbvie US LLC	07/31/2030
00074-3473-03LUPRON DEPOT 45MG 6MO KIT	$753.77	FSS	Abbvie US LLC	07/31/2030
00074-3473-03LUPRON DEPOT 45MG 6MO KIT	$753.77	Big4	Abbvie US LLC	07/31/2030

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

API Supply Chain15 active DMFs9 inactive

15 active API suppliers hold Drug Master Files for this ingredient.

TAKEDA PHARMACEUTICAL CO LTDLEUPROLIDE ACETATE

DMF 104161993

POLYPEPTIDE LABORATORIES INCLEUPROLIDE

DMF 131501998

BACHEM AGLEUPROLIDE ACETATE

DMF 138221998

CHEMI SPALEUPROLIDE ACETATE

DMF 147632000

PIRAMAL PHARMA LTDLEUPROLIDE ACETATE

DMF 251282011

BCN PEPTIDES SALEUPROLIDE (LEUPRORELIN)

DMF 267162012

POLYPEPTIDE LABORATORIES SWEDEN ABLEUPROLIDE ACETATE

DMF 268322013

SUN PHARMACEUTICAL INDUSTRIES LTDLEUPROLIDE ACETATE USP

DMF 278322014

AURO PEPTIDES LTDLEUPROLIDE ACETATE USP

DMF 311702016

MATRIX PHARMACORP PRIVATE LTDLEUPROLIDE ACETATE USP

DMF 322952017

REALI TIDE BIOLOGICAL TECHNOLOGY (WEIHAI) CO LTDLEUPROLIDE ACETATE

DMF 337652019

ALP PHARM BEIJING CO LTDLEUPROLIDE ACETATE

DMF 348472020

ZHEJIANG PEPTITES BIOTECH CO LTDLEUPROLIDE ACETATE

DMF 350712020

SHANXI TONGDA PHARMACEUTICAL CO LTDLEUPROLIDE ACETATE

DMF 405562024

ALEMBIC PHARMACEUTICALS LTDLEUPROLIDE ACETATE USP

DMF 412602025

BACHEM AMERICAS INCInactiveLEUPROLIDE ACETATE

DMF 112361994

SPECGX LLCInactiveLEUPROLIDE ACETATE

DMF 120521996

PENINSULA LABS INCInactiveLEUPROLIDE

DMF 139221998

GENZYME CORPInactiveLEUPROLIDE ACETATE

DMF 144401999

LIPOTEC SAInactiveLEUPROLIDE ACETATE NON-STERILE BULK DRUG SUBSTANCE

DMF 151642000

TEVA PHARMACEUTICAL INDUSTRIES LTDInactiveLEUPROLIDE ACETATE

DMF 151892000

SPECGX LLCInactiveLEUPROLIDE ACETATE (SPECIAL)

DMF 248452013

AMBIOPHARM INCInactiveLEUPROLIDE, NON-STERILE, BULK DRUG SUBSTANCE

DMF 263802012

CHINESE PEPTIDE COInactiveLEUPROLIDE ACETATE

DMF 293552015

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

21 letters from Drugs@FDA

Date	Submission	Document
Aug 19, 2025	SUPPL -47	View Letter (PDF)
Mar 22, 2024	SUPPL -46	View Letter (PDF)
Dec 5, 2023	SUPPL -45	View Letter (PDF)
Apr 19, 2022	SUPPL -43	View Letter (PDF)
Mar 7, 2019	SUPPL -42	View Letter (PDF)
Dec 20, 2018	SUPPL -41	View Letter (PDF)
Jun 8, 2016	SUPPL -38	View Letter (PDF)
Jul 1, 2014	SUPPL -36	View Letter (PDF)
Jul 12, 2013	SUPPL -35	View Letter (PDF)
Jul 20, 2012	SUPPL -33	View Letter (PDF)
Jun 29, 2011	SUPPL -25	View Letter (PDF)
Jun 29, 2011	SUPPL -30	View Letter (PDF)
Jun 29, 2011	SUPPL -32	View Letter (PDF)
Jan 20, 2011	SUPPL -31	View Letter (PDF)
May 4, 2010	SUPPL -29	View Letter (PDF)
May 4, 2010	SUPPL -28	View Letter (PDF)
May 4, 2010	SUPPL -24	View Letter (PDF)
Oct 20, 2005	SUPPL -18	View Letter (PDF)
Oct 20, 2005	SUPPL -19	View Letter (PDF)
Jan 14, 2004	SUPPL -16	View Letter (PDF)
Sep 25, 2003	SUPPL -13	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (3)

Sort:

#001 — 22.5MG

RLD

0 patents0 exclusivities▴

INJECTABLE;INJECTION | Approved: Dec 22, 1995

No patent or exclusivity listings for this strength.

#002 — 30MG

RLD

0 patents0 exclusivities▾

INJECTABLE;INJECTION | Approved: May 30, 1997

#003 — 45MG

RLD

2 patents0 exclusivities▾

INJECTABLE;INJECTION | Approved: Jun 17, 2011